Ductal adenocarcinoma of pancreas

14 trials 8 recruiting MedDRA PT
14 Registered trials
8 Recruiting
10 Unique sponsors
12 Unique IMPs
14 Commercial trials
Drug classes (ATC)
— ATC code not specified 11
L Oncology (ATC L) 2
S Ophthalmology/ENT (ATC S) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 7 substances
Kinase inhibitor 1 substance
Antimetabolite 1 substance
Taxane 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Phase III: 2 Phase I/II: 1 Phase I: 7 Phase I (Other): 1 Phase I (First in Human): 3

Filter these 14 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 14 trials

Phase III

2 trials
  • Merck Sharp & Dohme LLC Commercial
    BELZUTIFAN; LENVATINIB
    2025-524160-38-00 10 countries 2026 n=37
    Recruiting
  • Revolution Medicines Inc. Commercial
    (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    2025-523495-23-00 4 countries n=98
    Pending

Phase I/II

1 trial
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB; SACITUZUMAB TIRUMOTECAN
    2023-508703-21-00 2 countries 2024 n=20
    Recruiting

Phase I

7 trials
  • Amgen Inc. Commercial
    IMP not specified
    2025-521707-48-00 7 countries 2025 n=135
    Recruiting
  • Beigene Ltd. Commercial
    IMP not specified
    2023-505322-34-00 1 country 2024 n=45
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2024-515307-19-00 3 countries 2025 n=79
    Recruiting
  • Merck Healthcare KGaA Commercial
    IMP not specified
    2025-523232-39-00 1 country n=14
    Pending
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-510356-23-00 6 countries 2025 n=76
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2025-521702-18-00 5 countries 2026 n=62
    Recruiting
  • Pfizer Inc. Commercial
    IMP not specified
    2024-517988-23-00 2 countries n=61
    Ended

Phase I (Other)

1 trial
  • Amgen Inc. Commercial
    IMP not specified
    2024-511195-33-00 8 countries 2024 n=81
    Ended

Phase I (First in Human)

3 trials
  • Amgen Inc. Commercial
    AMG 193
    2023-504363-17-00 4 countries 2022 n=98
    Ended
  • Eir Biotherapies S.r.l. Commercial
    AUTOLOGOUS HUMAN ADIPOSE PERIVASCULAR STROMAL CELLS GENETICALLY MODIFIED TO SECRETE SOLUBLE TUMOUR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND; GEMCITABINE; PACLITAXEL ALBUMIN-BOUND
    2024-516019-26-00 1 country 2025 n=18 Orphan
    Recruiting
  • ITM Oncologics GmbH Commercial
    177LU-DPI-4452; 68GA-DPI-4452; ACETAZOLAMIDE
    2023-504254-35-00 2 countries 2023 n=97
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amgen Inc. Commercial 3 Phase I, Phase I (Other), Phase I (First in Human) 1
Novartis Pharma AG Commercial 2 Phase I 2
Merck Sharp & Dohme LLC Commercial 2 Phase III, Phase I/II 2
Beigene Ltd. Commercial 1 Phase I 0
BeOne Medicines AG Commercial 1 Phase I 1
Merck Healthcare KGaA Commercial 1 Phase I 0
Pfizer Inc. Commercial 1 Phase I 0
Revolution Medicines Inc. Commercial 1 Phase III 0
Eir Biotherapies S.r.l. Commercial 1 Phase I (First in Human) 1
ITM Oncologics GmbH Commercial 1 Phase I (First in Human) 1
New trials by year
2022
1
2023
1
2024
3
2025
4
2026
2
← All indication landscapes